Piotr Leszczyński

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)

Gerd R Burmester, Andrea Rubbert‐Roth, Alain Cantagrel et al. · Annals of the Rheumatic Diseases · 2013 · 238 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

Megan E. B. Clowse, Daniel J. Wallace, Richard Furie et al. · Arthritis & Rheumatology · 2016 · 236 citations · Full text

Life Sciences, Clinical Sciences, Immunology +17

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

Paul Emery, Jiří Vencovský, Anna Sylwestrzak et al. · Annals of the Rheumatic Diseases · 2015 · 229 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)

Gerd R Burmester, Andrea Rubbert‐Roth, Alain Cantagrel et al. · Annals of the Rheumatic Diseases · 2015 · 123 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus

Richard Furie, Ian N Bruce, Thomas Dörner et al. · Lara D. Veeken · 2021 · 123 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15